Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3. Yaari R, Holdridge KC, Williamson M, Wessels AM, et al. Alzheimers Dement 2025;21:e70662.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yaari R, Holdridge KC, Williamson M, Wessels AM, et al. Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3. Alzheimers Dement 2025;21:e70662.
PMID: 40955720